{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:30Z","timestamp":1793037630009,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To explore the quality of life (QOL) in patients with myasthenia gravis (MG) and factors associated with QOL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational study included patients with MG diagnosed at the First Affiliated Hospital of Fujian Medical University between January 2020 and March 2022. The QOL of patients was evaluated with the 15-item Myasthenia Gravis Quality of Life (MG-QOL15). Current MG severity was evaluated with MGFA grade, MG-ADL score, MGC score, and MGFA Postintervention Status. The data about gender, age of onset, subgroup, antibodies, age, duration, education, employment state, marital status, skeletal muscle affected, thymic histology, and current treatment methods of the patient were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 185 patients [72 males (38.9%), aged 45.2 years (14\u201377)] with MG were enrolled. Age at onset was 38.3 \u00b1 17.9 years, and disease duration was 87.9 months (0\u2013672). The median MG-QOL15 score was 12.5 (0\u201358). The item \u201chave trouble using my eyes\u201d was the highest scoring item in both ocular and generalized patients with MG. The MG-QOL15 score was significantly different among patients with OMG (9.2 \u00b1 9.4, <jats:italic>n<\/jats:italic> = 63), GMG (9.0 \u00b1 8.8, <jats:italic>n<\/jats:italic> = 22), and BMG (15.4 \u00b1 14.2, <jats:italic>n<\/jats:italic> = 100) (<jats:italic>P<\/jats:italic> = 0.018). Patients with BMG had higher MG-QOL15 scores than OMG (<jats:italic>P<\/jats:italic> = 0.001) and GMG (<jats:italic>P<\/jats:italic> = 0.009), but there was no significant difference between OMG and GMG (<jats:italic>P<\/jats:italic> = 0.467). The MG-QOL15 score was significantly lower in patients who had undergone thymectomy (9.7 \u00b1 9.8, <jats:italic>n<\/jats:italic> = 58) compared to those who had not (13.8 \u00b1 13.4, <jats:italic>n<\/jats:italic> = 127, <jats:italic>P<\/jats:italic> = 0.022). MG-QOL15 score was significantly lower in patients who underwent thymectomy compared to those who did not (9.7 \u00b1 9.8, <jats:italic>n<\/jats:italic> = 58 vs. 13.8 \u00b1 13.4, <jats:italic>n<\/jats:italic> = 127, <jats:italic>P<\/jats:italic> = 0.022). MG-QOL15 score was different among MGFA grades (Remission: 5.2 \u00b1 5.4, <jats:italic>n<\/jats:italic> = 41; I: 11.3 \u00b1 10, <jats:italic>n<\/jats:italic> = 61; II: 11.6 \u00b1 11.1, <jats:italic>n<\/jats:italic> = 40; III: 18.1 \u00b1 12.1, <jats:italic>n<\/jats:italic> = 29; and IVa: 30.1 \u00b1 20, <jats:italic>n<\/jats:italic> = 14, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). There was no significant difference between patients in MGFA grade I and II (<jats:italic>P<\/jats:italic> = 0.896), and there was no significant difference between patients in MGFA grade III and IVa (<jats:italic>P<\/jats:italic> = 0.052). MG-ADL (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) and MGC (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) were positively correlated with MG-QOL15. Men had higher MG-QOL15 than women (<jats:italic>P<\/jats:italic> = 0.094), and LOMG had higher MG-QOL15 than EOMG (<jats:italic>P<\/jats:italic> = 0.072). Multivariate linear regression identified that higher MG-ADL (<jats:italic>P<\/jats:italic> &amp;lt; 0.001), higher MGC (<jats:italic>P<\/jats:italic> = 0.02), and poor employment status (<jats:italic>P<\/jats:italic> = 0.045) were independently associated with higher MG-QOL15.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Having trouble using the eyes accounted for the highest score in MG-QOL15, eye symptoms affect QOL more than limb weakness in MG. Daily life activity, disease severity, and employment status were associated with patients' QOL. Adequate treatment should be applied to improve QOL, while mild symptoms can be accepted. Men and patients over the age of 50 years of onset may need more attention.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1072861","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:57:18Z","timestamp":1673506638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China"],"prefix":"10.3389","volume":"13","author":[{"given":"Xuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Bin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac."},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.pmrj.2010.04.012","article-title":"Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis","volume":"2","author":"Cantor","year":"2010","journal-title":"PM R."},{"key":"B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard JF","year":"2019","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4103\/0028-3886.181542","article-title":"MG-QoL-15 scores in treated myasthenia gravis: experience from a university hospital in India","volume":"64","author":"Kumar","year":"2016","journal-title":"Neurol India."},{"key":"B15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1590\/0004-282x20160129","article-title":"Brazilian-Portuguese translation, cross-cultural adaptation and validation of the Myasthenia Gravis Composite scale. A multicentric study","volume":"74","author":"Oliveira","year":"2016","journal-title":"Arq Neuropsiquiatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mus.26313","article-title":"Translation, cross-cultural adaptation, and validation of the Chinese version of the 15-item myasthenia gravis quality of life questionnaire","volume":"59","author":"Miao","year":"2019","journal-title":"Muscle Nerve."},{"key":"B17","doi-asserted-by":"publisher","first-page":"g7818","DOI":"10.1136\/bmj.g7818","article-title":"Patient reported outcome measures in practice","volume":"350","author":"Nelson","year":"2015","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"553626","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of quality of life in myasthenia gravis patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes."},{"key":"B20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5582\/irdr.2019.01121","article-title":"Quality of life in refractory generalized myasthenia gravis: a rapid review of the literature","volume":"8","author":"Garz\u00f3n-Orjuela","year":"2019","journal-title":"Intractable Rare Dis Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0206754","DOI":"10.1371\/journal.pone.0206754","article-title":"Factors associated with quality of life of people with myasthenia gravis","volume":"13","author":"Jeong","year":"2018","journal-title":"PLoS ONE."},{"key":"B24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","article-title":"Quality of life in 188 patients with myasthenia gravis in China","volume":"126","author":"Yang","year":"2016","journal-title":"Int J Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","article-title":"Gender differences in quality of life among patients with myasthenia gravis in China","volume":"18","author":"Dong","year":"2020","journal-title":"Health Qual Life Outcomes."},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jocn.2020.06.023","article-title":"Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China","volume":"79","author":"Fan","year":"2020","journal-title":"J Clin Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard JF","year":"2020","journal-title":"JAMA Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Shrager","year":"2016","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e013278","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/neurolint14020033","article-title":"Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: data from an Italian cohort","volume":"14","author":"Lupica","year":"2022","journal-title":"Neurol Int."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1072861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:57:21Z","timestamp":1673506641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1072861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":33,"alternative-id":["10.3389\/fneur.2022.1072861"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1072861","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"article-number":"1072861"}}